Laminar shear stress-based therapy for pulmonary fibrosis: Laminar shear stress decreases miR-34 expression, increases Sirtuin-1 expression, suppresses tumor suppressor p53 acetylation, prevents apoptosis in Alveolar epithelial cell (AEC), and improves pulmonary fibrosis via up regulation of its target gene, 22/May/2017, 11.54 pm

Amino-acid based therapy for Inflammatory bowel disease: Leucine, the branched chain amino acid, decreases the expression of oncostatin M, attenuates activation of oncostatin M- oncostatin M receptor pathway in inflamed colon tissues, inhibits inflammatory gene expression, attenuates colonic pathogenesis, and inhibits the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 22/May/2017, 11.50 pm
May 22, 2017
Amino-acid based therapy for Glaucoma: L-Leucine, the branched chain amino acid, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma via down regulation of its target gene, 22/May/2017, 11. 55 pm
May 22, 2017
Show all

What we say: 

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Laminar shear stress-based therapy for pulmonary fibrosis: Laminar shear stress decreases miR-34 expression, increases Sirtuin-1 expression, suppresses tumor suppressor p53 acetylation, prevents apoptosis in Alveolar epithelial cell (AEC), and improves pulmonary fibrosis via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) Idiopathic pulmonary disease (IPD)/Idiopathic pulmonary fibrosis (IPF)  is a progressive degenerative disease of the lung, with debilitating consequences; (2) drugs that are currently used to treat IPF are ineffective; and (3) 6.8-16.3 per 100,000 persons suffer from  Idiopathic pulmonary disease, there is an urgent need to find: (i) a way to induce regeneration of lung cells in pulmonary fibrosis patients; (ii) side-effect-free natural product-based drug; and (iii) a way to effectively treat and cure PF


From research findings to therapeutic opportunity

This study suggests, for the first time, that Laminar shear stress, by increasing the expression of its target gene, it may: (1) decrease the expression of tumor suppressor p53 and its target gene miR-34a; (2) increase the expression of longevity-protein Sirtuin-1; (3) suppress p53 acetylation; (4) inhibit urokinase-type plasminogen activator and the urokinase-type plasminogen activator receptor expression in AECs (Alveolar epithelial cells); (5) prevent apoptosis in AECs; and (6) inhibit the development and progression of pulmonary fibrosis. 

Thus, physicians/pulmonologists may consider encouraging their patients to undergo Laminar shear stress therapy. Taken together, Laminar shear stress therapy may be used to  treat pulmonary fibrosis.

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How Laminar shear stress decreases miR-34 expression to improve pulmonary fibrosis

Amount: $100#

# Research cooperation


References

CitationBoominathan, L., Laminar shear stress-based therapy for pulmonary fibrosis: Laminar shear stress decreases miR-34 expression, increases Sirtuin-1 expression, suppresses tumor suppressor p53 acetylation, prevents apoptosis in Alveolar epithelial cell (AEC), and improves pulmonary fibrosis via up regulation of its target gene, 22/May/2017, 11.54 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite, kind drop us a line at admin@genoemdiscovery.org

Comments are closed.